BIOGEN IDEC - Diversification and Strong Foothold in MS to Reign
We continue to like Biogen Idec (BIIB) as next year is also going to be eventful: Approval and launch of BG-12 (dimethyl fumerate, under review with FDA & EMEA, est. PDUFA: late Mar. 2013, peak sales potential ww – $2.5b by 2018) and clinical news flow from its late stage pipeline products. BIIB revised its FY12 sales growth guidance upwards (from mid-single digits to mid to high-single digits) on growing volumes despite growing competition in the MS therapy area. For more details on the upcoming catalysts, please read our report released on 7th Nov. 2012, titled, “Biogen Idec - Diversification and Strong Foothold in MS to Reign”.
